Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Capital Markets

Mabwell (Shanghai) Bioscience / Equity Capital Markets

<ul>
<li>Mabwell (Shanghai) Bioscience launched HK IPO consisting of 47M H shares. The indicative offer price range is HK$27.64–30.71 per share. The company seeks to raise ~$185M.</li>
<li>Subscriptions will close on April 23, 2026, with expected listing on April 28, 2026. Citic Securities and Haitong are the joint sponsors to the issue. </li>
<li>The company intends to utilize IPO proceeds for advancing the clinical development trials of its lead drug candidate and other pipeline products, and to establish sales and marketing team.</li>
</ul>


Mabwell (Shanghai) Bioscience launched HK IPO consisting of 47M H shares. The indicative offer price range is HK$27.64–30.71 per share. The company seeks to raise ~$185M.
Subscriptions will close on April 23, 2026, with expected listing on April 28, 2026. Citic Securities and Haitong are the joint sponsors to the issue. 
The company intends to utilize IPO proceeds for advancing the clinical development trials of its lead drug candidate and other pipeline products, and to establish sales and marketing team.


Mabwell (Shanghai) Bioscience IPO: Aiming for Next Level of Growth Riding on ADC Pipeline